Flaherty & Crumrine Preferred Income Opportunity Fund (PFO) Competitors

Flaherty & Crumrine Preferred Income Opportunity Fund (NYSE:PFO) and VanEck Biotech ETF (NASDAQ:BBH) are both small-cap finance companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.

Which has preferable valuation & earnings, PFO or BBH?

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Flaherty & Crumrine Preferred Income Opportunity Fund	N/A	N/A	N/A	N/A	N/A
VanEck Biotech ETF	N/A	N/A	N/A	N/A	N/A

Does the media favor PFO or BBH?

In the previous week, VanEck Biotech ETF had 1 more articles in the media than Flaherty & Crumrine Preferred Income Opportunity Fund. MarketBeat recorded 3 mentions for VanEck Biotech ETF and 2 mentions for Flaherty & Crumrine Preferred Income Opportunity Fund. Flaherty & Crumrine Preferred Income Opportunity Fund's average media sentiment score of 1.48 beat VanEck Biotech ETF's score of 0.62 indicating that Flaherty & Crumrine Preferred Income Opportunity Fund is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Flaherty & Crumrine Preferred Income Opportunity Fund	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
VanEck Biotech ETF	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is PFO or BBH a better dividend stock?

Flaherty & Crumrine Preferred Income Opportunity Fund pays an annual dividend of $0.55 per share and has a dividend yield of 6.6%. VanEck Biotech ETF pays an annual dividend of $0.71 per share and has a dividend yield of 0.4%.

Does the MarketBeat Community favor PFO or BBH?

VanEck Biotech ETF received 38 more outperform votes than Flaherty & Crumrine Preferred Income Opportunity Fund when rated by MarketBeat users.

Company	Underperform	Outperform
Flaherty & Crumrine Preferred Income Opportunity Fund	N/A	N/A
VanEck Biotech ETF	Outperform Votes 38 65.52%	Underperform Votes 20 34.48%

Do analysts rate PFO or BBH?

Given VanEck Biotech ETF's higher probable upside, analysts plainly believe VanEck Biotech ETF is more favorable than Flaherty & Crumrine Preferred Income Opportunity Fund.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Flaherty & Crumrine Preferred Income Opportunity Fund	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
VanEck Biotech ETF	0 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.59

Do institutionals and insiders have more ownership in PFO or BBH?

12.9% of Flaherty & Crumrine Preferred Income Opportunity Fund shares are owned by institutional investors. Comparatively, 32.1% of VanEck Biotech ETF shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Is PFO or BBH more profitable?

Company	Net Margins	Return on Equity	Return on Assets
Flaherty & Crumrine Preferred Income Opportunity Fund	N/A	N/A	N/A
VanEck Biotech ETF	N/A	N/A	N/A

Which has more risk & volatility, PFO or BBH?

Flaherty & Crumrine Preferred Income Opportunity Fund has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500. Comparatively, VanEck Biotech ETF has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500.

Summary

VanEck Biotech ETF beats Flaherty & Crumrine Preferred Income Opportunity Fund on 5 of the 8 factors compared between the two stocks.